<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p190" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_190{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_190{left:306px;bottom:30px;}
#t3_190{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_190{left:346px;bottom:30px;}
#t5_190{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_190{left:517px;bottom:30px;}
#t7_190{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_190{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_190{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_190{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_190{left:35px;bottom:777px;letter-spacing:0.43px;}
#tc_190{left:35px;bottom:748px;letter-spacing:0.11px;word-spacing:0.08px;}
#td_190{left:35px;bottom:724px;letter-spacing:0.09px;word-spacing:-1.13px;}
#te_190{left:260px;bottom:724px;letter-spacing:0.13px;word-spacing:-0.29px;}
#tf_190{left:35px;bottom:701px;letter-spacing:0.08px;}
#tg_190{left:35px;bottom:660px;letter-spacing:-0.08px;word-spacing:0.76px;}
#th_190{left:35px;bottom:632px;letter-spacing:0.11px;word-spacing:0.07px;}
#ti_190{left:35px;bottom:608px;letter-spacing:0.11px;word-spacing:0.08px;}
#tj_190{left:35px;bottom:585px;letter-spacing:-0.03px;word-spacing:0.21px;}
#tk_190{left:35px;bottom:562px;letter-spacing:0.2px;word-spacing:-0.02px;}
#tl_190{left:35px;bottom:539px;letter-spacing:0.1px;word-spacing:0.08px;}
#tm_190{left:35px;bottom:515px;letter-spacing:0.14px;word-spacing:-0.63px;}
#tn_190{left:35px;bottom:492px;letter-spacing:0.08px;word-spacing:-0.88px;}
#to_190{left:35px;bottom:469px;letter-spacing:0.06px;word-spacing:0.13px;}
#tp_190{left:35px;bottom:446px;letter-spacing:0.11px;word-spacing:0.07px;}
#tq_190{left:35px;bottom:405px;letter-spacing:0.2px;}
#tr_190{left:35px;bottom:376px;letter-spacing:0.14px;word-spacing:0.04px;}
#ts_190{left:35px;bottom:353px;letter-spacing:0.04px;word-spacing:0.15px;}
#tt_190{left:35px;bottom:330px;letter-spacing:0.04px;word-spacing:0.14px;}
#tu_190{left:35px;bottom:308px;letter-spacing:0.11px;word-spacing:-0.67px;}
#tv_190{left:35px;bottom:284px;letter-spacing:-0.06px;word-spacing:0.25px;}
#tw_190{left:35px;bottom:246px;letter-spacing:-0.13px;word-spacing:0.55px;}
#tx_190{left:35px;bottom:222px;letter-spacing:0.13px;word-spacing:0.05px;}
#ty_190{left:35px;bottom:199px;letter-spacing:0.09px;word-spacing:0.09px;}
#tz_190{left:35px;bottom:176px;letter-spacing:0.06px;word-spacing:0.13px;}
#t10_190{left:35px;bottom:152px;letter-spacing:0.12px;word-spacing:-1.16px;}
#t11_190{left:362px;bottom:152px;letter-spacing:-0.12px;word-spacing:-0.92px;}
#t12_190{left:35px;bottom:129px;letter-spacing:0.23px;word-spacing:-0.04px;}
#t13_190{left:155px;bottom:129px;letter-spacing:0.31px;}
#t14_190{left:205px;bottom:129px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t15_190{left:350px;bottom:129px;letter-spacing:0.12px;word-spacing:0.07px;}
#t16_190{left:494px;bottom:137px;letter-spacing:0.1px;}
#t17_190{left:539px;bottom:129px;letter-spacing:0.42px;}
#t18_190{left:35px;bottom:106px;letter-spacing:0.1px;word-spacing:0.08px;}
#t19_190{left:35px;bottom:83px;letter-spacing:0.12px;word-spacing:-1.16px;}
#t1a_190{left:314px;bottom:90px;letter-spacing:-0.01px;}
#t1b_190{left:337px;bottom:83px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1c_190{left:35px;bottom:60px;letter-spacing:0.11px;word-spacing:-0.39px;}
#t1d_190{left:618px;bottom:777px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1e_190{left:618px;bottom:754px;letter-spacing:-0.03px;word-spacing:0.21px;}
#t1f_190{left:790px;bottom:761px;letter-spacing:-0.01px;}
#t1g_190{left:813px;bottom:754px;letter-spacing:0.08px;word-spacing:0.11px;}
#t1h_190{left:618px;bottom:731px;letter-spacing:0.11px;word-spacing:-0.98px;}
#t1i_190{left:618px;bottom:707px;letter-spacing:0.17px;word-spacing:0.02px;}
#t1j_190{left:618px;bottom:684px;letter-spacing:0.08px;word-spacing:-1.12px;}
#t1k_190{left:879px;bottom:692px;letter-spacing:0.1px;}
#t1l_190{left:924px;bottom:684px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1m_190{left:618px;bottom:661px;letter-spacing:0.04px;word-spacing:-0.04px;}
#t1n_190{left:618px;bottom:638px;letter-spacing:0.1px;word-spacing:0.08px;}
#t1o_190{left:618px;bottom:614px;letter-spacing:0.07px;word-spacing:-0.87px;}
#t1p_190{left:939px;bottom:614px;letter-spacing:0.08px;word-spacing:-0.71px;}
#t1q_190{left:618px;bottom:591px;letter-spacing:0.23px;word-spacing:-1.27px;}
#t1r_190{left:736px;bottom:591px;letter-spacing:0.3px;}
#t1s_190{left:783px;bottom:591px;letter-spacing:0.04px;word-spacing:-1.08px;}
#t1t_190{left:923px;bottom:591px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1u_190{left:1067px;bottom:599px;letter-spacing:0.13px;}
#t1v_190{left:618px;bottom:568px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1w_190{left:618px;bottom:545px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1x_190{left:1065px;bottom:552px;}
#t1y_190{left:1071px;bottom:545px;letter-spacing:-0.15px;word-spacing:0.33px;}
#t1z_190{left:618px;bottom:522px;letter-spacing:0.16px;word-spacing:0.02px;}
#t20_190{left:981px;bottom:529px;letter-spacing:0.06px;}
#t21_190{left:1049px;bottom:522px;letter-spacing:0.1px;word-spacing:0.08px;}
#t22_190{left:618px;bottom:498px;letter-spacing:0.09px;word-spacing:0.09px;}
#t23_190{left:618px;bottom:475px;letter-spacing:0.09px;word-spacing:0.09px;}
#t24_190{left:618px;bottom:452px;letter-spacing:-0.07px;}
#t25_190{left:759px;bottom:459px;letter-spacing:0.1px;}
#t26_190{left:618px;bottom:413px;letter-spacing:0.15px;word-spacing:-0.24px;}
#t27_190{left:618px;bottom:390px;letter-spacing:0.27px;}
#t28_190{left:658px;bottom:390px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t29_190{left:618px;bottom:366px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t2a_190{left:618px;bottom:343px;letter-spacing:0.25px;}
#t2b_190{left:684px;bottom:343px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2c_190{left:618px;bottom:320px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2d_190{left:978px;bottom:320px;letter-spacing:0.1px;word-spacing:0.08px;}
#t2e_190{left:618px;bottom:297px;letter-spacing:0.39px;}
#t2f_190{left:688px;bottom:297px;letter-spacing:0.07px;word-spacing:0.12px;}
#t2g_190{left:618px;bottom:273px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2h_190{left:618px;bottom:250px;letter-spacing:0.12px;word-spacing:0.06px;}
#t2i_190{left:827px;bottom:250px;letter-spacing:0.18px;word-spacing:0.02px;}
#t2j_190{left:618px;bottom:227px;letter-spacing:0.19px;}
#t2k_190{left:865px;bottom:227px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2l_190{left:618px;bottom:204px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2m_190{left:618px;bottom:165px;letter-spacing:-0.24px;word-spacing:0.67px;}
#t2n_190{left:618px;bottom:141px;letter-spacing:0.01px;word-spacing:0.17px;}
#t2o_190{left:618px;bottom:118px;letter-spacing:0.09px;word-spacing:-0.67px;}
#t2p_190{left:618px;bottom:95px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2q_190{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_190{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_190{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_190{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_190{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_190{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_190{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s6_190{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s7_190{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s8_190{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s9_190{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts190" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg190Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg190" style="-webkit-user-select: none;"><object width="1210" height="935" data="190/190.svg" type="image/svg+xml" id="pdf190" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_190" class="t s0_190">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_190" class="t s1_190">© </span>
<span id="t3_190" class="t s0_190">(NCCN </span>
<span id="t4_190" class="t s1_190">© </span>
<span id="t5_190" class="t s0_190">), All rights reserved. NCCN Guidelines </span>
<span id="t6_190" class="t s1_190">® </span>
<span id="t7_190" class="t s0_190">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_190" class="t s2_190">NCCN Guidelines Version 4.2024 </span>
<span id="t9_190" class="t s2_190">Head and Neck Cancers </span>
<span id="ta_190" class="t s3_190">MS-49 </span>
<span id="tb_190" class="t s3_190">Follow-up </span>
<span id="tc_190" class="t s4_190">Recommendations for surveillance are provided in the algorithm (see </span>
<span id="td_190" class="t s5_190">Follow-up Recommendations </span><span id="te_190" class="t s4_190">in the NCCN Guidelines for Head and Neck </span>
<span id="tf_190" class="t s4_190">Cancers). </span>
<span id="tg_190" class="t s6_190">Very Advanced Head and Neck Cancers </span>
<span id="th_190" class="t s4_190">The algorithms for very advanced H&amp;N cancers include: 1) newly </span>
<span id="ti_190" class="t s4_190">diagnosed locally advanced T4b (M0); 2) newly diagnosed unresectable </span>
<span id="tj_190" class="t s4_190">regional nodal disease, typically N3; 3) metastatic disease at initial </span>
<span id="tk_190" class="t s4_190">presentation (M1); or 4) recurrent or persistent disease. The treatment </span>
<span id="tl_190" class="t s4_190">goal is usually cure for patients with newly diagnosed locoregional but </span>
<span id="tm_190" class="t s4_190">unresectable disease. For recurrent disease, the goal is cure if surgery or </span>
<span id="tn_190" class="t s4_190">radiation remains feasible, or palliation if the patient has received previous </span>
<span id="to_190" class="t s4_190">RT and the disease is unresectable. For patients with widely metastatic </span>
<span id="tp_190" class="t s4_190">disease, the goal is palliation or prolongation of life. </span>
<span id="tq_190" class="t s3_190">Treatment </span>
<span id="tr_190" class="t s4_190">The treatment of patients with unresectable locoregional, persistent, </span>
<span id="ts_190" class="t s4_190">recurrent, or metastatic H&amp;N cancers is dictated by the patient’s PS and </span>
<span id="tt_190" class="t s4_190">intent of treatment (ie, palliative vs. curative). Patients with good PS may </span>
<span id="tu_190" class="t s4_190">tolerate a wide range of treatment options, whereas patients with reduced </span>
<span id="tv_190" class="t s4_190">PS cannot. </span>
<span id="tw_190" class="t s7_190">Newly Diagnosed Locoregionally Advanced Disease </span>
<span id="tx_190" class="t s4_190">In patients with a PS of 0 or 1, the recommended treatment of newly </span>
<span id="ty_190" class="t s4_190">diagnosed, very advanced disease is concurrent systemic therapy/RT, </span>
<span id="tz_190" class="t s4_190">with a large amount of phase III data supporting high-dose cisplatin as a </span>
<span id="t10_190" class="t s4_190">category 1 preferred recommendation (see </span><span id="t11_190" class="t s5_190">Primary Systemic Therapy with </span>
<span id="t12_190" class="t s5_190">Concurrent RT </span><span id="t13_190" class="t s4_190">under </span><span id="t14_190" class="t s5_190">Systemic Therapy </span><span id="t15_190" class="t s4_190">in this Discussion). </span>
<span id="t16_190" class="t s8_190">264,288 </span>
<span id="t17_190" class="t s4_190">There </span>
<span id="t18_190" class="t s4_190">are also considerable phase III data from Europe that support the use of </span>
<span id="t19_190" class="t s4_190">carboplatin/5-FU with concurrent RT. </span>
<span id="t1a_190" class="t s8_190">177 </span>
<span id="t1b_190" class="t s4_190">This treatment is also considered </span>
<span id="t1c_190" class="t s4_190">a category 1 preferred option. Cisplatin-based induction systemic therapy </span>
<span id="t1d_190" class="t s4_190">has been studied, followed by RT alone or chemoradiation with a weekly </span>
<span id="t1e_190" class="t s4_190">platinum or cetuximab. </span>
<span id="t1f_190" class="t s8_190">314 </span>
<span id="t1g_190" class="t s4_190">However, an improvement in OS with the </span>
<span id="t1h_190" class="t s4_190">incorporation of induction chemotherapy, compared to proceeding directly </span>
<span id="t1i_190" class="t s4_190">to state-of-the-art concurrent systemic therapy/RT, has not been </span>
<span id="t1j_190" class="t s4_190">established in randomized studies. </span>
<span id="t1k_190" class="t s8_190">306,307 </span>
<span id="t1l_190" class="t s4_190">Cetuximab with concurrent RT is </span>
<span id="t1m_190" class="t s4_190">a category 2B option based on phase II and phase III data but is distinctly </span>
<span id="t1n_190" class="t s4_190">inferior to cisplatin with concurrent RT, particularly in patients with HPV- </span>
<span id="t1o_190" class="t s4_190">positive disease, as discussed above (see </span><span id="t1p_190" class="t s5_190">Primary Systemic Therapy with </span>
<span id="t1q_190" class="t s5_190">Concurrent RT </span><span id="t1r_190" class="t s4_190">under </span><span id="t1s_190" class="t s5_190">Systemic Therapy </span><span id="t1t_190" class="t s4_190">in this Discussion). </span>
<span id="t1u_190" class="t s8_190">140,282,285,286,621 </span>
<span id="t1v_190" class="t s4_190">Other chemoradiation options include carboplatin/paclitaxel (category 2B </span>
<span id="t1w_190" class="t s4_190">based on less panel consensus), weekly cisplatin 40 mg/m </span>
<span id="t1x_190" class="t s8_190">2 </span>
<span id="t1y_190" class="t s4_190">, and </span>
<span id="t1z_190" class="t s4_190">docetaxel (for patients not eligible for cisplatin). </span>
<span id="t20_190" class="t s8_190">140,622-625 </span>
<span id="t21_190" class="t s4_190">Category 2B </span>
<span id="t22_190" class="t s4_190">chemoradiation options that the panel has deemed useful only in select </span>
<span id="t23_190" class="t s4_190">circumstances are 5-FU/hydroxyurea, cisplatin with infusional 5-FU, and </span>
<span id="t24_190" class="t s4_190">cisplatin/paclitaxel. </span>
<span id="t25_190" class="t s8_190">626,627 </span>
<span id="t26_190" class="t s4_190">Other options for patients with a PS of 2–3 are described in the algorithm </span>
<span id="t27_190" class="t s4_190">(see </span><span id="t28_190" class="t s5_190">Very Advanced Head and Neck Cancer: Treatment of Newly </span>
<span id="t29_190" class="t s5_190">Diagnosed (M0) T4b, N0–3 or Unresectable Nodal Disease or Unfit for </span>
<span id="t2a_190" class="t s5_190">Surgery </span><span id="t2b_190" class="t s4_190">in the NCCN Guidelines for Head and Neck Cancers). Primary </span>
<span id="t2c_190" class="t s4_190">systemic therapy/RT regimens are listed in the </span><span id="t2d_190" class="t s5_190">Principles of Systemic </span>
<span id="t2e_190" class="t s5_190">Therapy </span><span id="t2f_190" class="t s4_190">in the NCCN Guidelines for Head and Neck Cancers. Radiation </span>
<span id="t2g_190" class="t s4_190">therapy fractionation for patients with newly diagnosed, very advanced </span>
<span id="t2h_190" class="t s4_190">disease is described in the </span><span id="t2i_190" class="t s5_190">Very Advanced Head and Neck Cancers: </span>
<span id="t2j_190" class="t s5_190">Principles of Radiation Therapy </span><span id="t2k_190" class="t s4_190">in the NCCN Guidelines for Head and </span>
<span id="t2l_190" class="t s4_190">Neck Cancers. </span>
<span id="t2m_190" class="t s7_190">Metastatic Disease </span>
<span id="t2n_190" class="t s4_190">For patients with metastatic (M1) disease at initial presentation, palliative </span>
<span id="t2o_190" class="t s4_190">adjunctive measures include RT, surgery, analgesics, and other therapies </span>
<span id="t2p_190" class="t s4_190">to control manifestations of disease spread (eg, pain, hypercalcemia, </span>
<span id="t2q_190" class="t s9_190">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
